‘All smiles': Prince Andrew wins fight against King Charles
After years of digging his heels in and refusing to leave his sprawling royal residence, the disgraced Duke of York is celebrating 'having won the Royal Lodge row,' the Express reports.
According to the outlet, Andrew has been 'all smiles' since finding out that his brother, King Charles, has given up trying to evict him — a stark contrast to his downcast outings earlier this year.
'Charles tried his best to get his non-working royal sibling to move to a smaller premises elsewhere to free up the royal home,' the outlet notes. As for how Andrew, 65, managed to emerge victorious in the fight over the royal digs, the duke presented Charles with 'a lease document that states he is legally entitled to stay there,' the outlet adds.
The feuding brothers have been locked in a bitter, yearslong spat over the property, located on the grounds of Windsor Castle, since 2019.
The Post has reached out to Buckingham Palace for comment.
Andrew was poised to leave the Royal Lodge after Charles refused to continue financially carrying his brother's weight.
However, it sensationally emerged in November that the shunned royal had found a mystery financial backer at the eleventh hour — allowing him to remain at the royal digs.
As a result, Charles responded by removing priceless items from the plush property over maintenance and security concerns.
Andrew has been living off a hefty allowance from the king's personal wealth for more than six years — ever since he was linked to disgraced late financier Jeffrey Epstein.
His weighty list of expenses includes $4 million (AU$5.9 million) worth of personal security per year, as well as a regular cash allowance — both of which Charles stopped providing in October 2024.
As a result, Andrew was ordered out of the 31-room property into the smaller Frogmore Cottage — but he refused.
The latter property has been sitting empty since Prince Harry and Meghan Markle handed over the keys in 2023.
It was previously reported that Charles had tried his all to downsize his scandal-scarred brother so that the Royal Lodge would free up for the Prince and Princess of Wales, as well as their three children.
However, the future king and queen later decided that the property didn't quite offer what they were looking for, much to Andrew's relief, as it meant there were no rivals for the home.
Prince William and Kate Middleton, for their part, have recently kick-started their search for their next family abode — meaning they are finally ready to bid adieu to Adelaide Cottage.
Andrew has resided at the lavish home since 2004. He currently lives there with his ex-wife, Sarah Ferguson.
Since finding an anonymous financial backer late last year, Andrew has faced recurring calls from the UK government to reveal the source of his mystery funding.
Exactly where the duke found the cash that enabled him to remain at the property is still unclear, as his only known steady income source is a Royal Navy pension.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Labor looks to speed up PBS listings amid calls from lobby groups
Health Minister Mark Butler says he is looking at recommendations to speed up medicine approvals amid pressure from lobbyists both within Australia and in the US. Medicines Australia has repeatedly highlighted that Australia lags behind comparable countries in listing new medicines on the Pharmaceutical Benefits Scheme (PBS) – a list of federally subsidised medicines. It takes an average of 466 days from when the Therapeutic Goods Administration approves a medicine to when it becomes affordable on the PBS, according to the peak body. This is much longer than in the UK and Canada, for example. The lengthy timeline has also angered the Pharmaceutical Research and Manufacturers of America (PhRMA), which has framed the PBS as a 'non-tariff trade barrier' that harms American companies in representations to the Trump administration. Lengthy PBS listing times is among PhRMA's core criticisms. Mr Butler said on Thursday he would look at Medicines Australia's recommendations to make the 'approvals system quicker'. 'We're getting an enormous number of new medicining coming on to the market,' he told the ABC. 'We're living through a turbocharged period of discovery bringing more and more new medicine, so making sure that we can assess them and approve them very quickly to get them into patients as quickly as possible is something I've said is a real priority for us this term.' Because the PBS compels drugmakers to negotiate prices with the federal government, PhRMA has accused Australia of 'freeloading' on US-funded research and development. Meanwhile, American consumers pick up the bill, according to the lobby group. 'The medicines industry, understandably, given their interest, want to make prices higher as well, so there will be a bit of a debate about how we do that,' Mr Butler said. 'But I'm very much on the page of getting medicines more quickly into our system, our PBS system. 'It's a terrific system and we're trying to make medicines cheaper at the same time for Australians.' PhRMA has explicitly urged the Trump administration to 'leverage ongoing trade negotiations' to influence Australia's PBS policies. Mr Butler has echoed Anthony Albanese and fellow senior government ministers in ruling out any 'compromise' on the system as part of tariff talks. For the moment, Donald Trump's concern with the sector appears to be largely focused on bringing down prices in the US rather than punishing allies for having cheaper medicines. A RAND Corporation report found that Americans pay nearly four times more than Australians for medicines and about three times more than the average in other developed economies. The answer, according to the US President, is to make pharmaceuticals in the US. In a warning shot to firms, Mr Trump this week threatened to slap tariffs of up to 250 per cent on foreign-made products. With Australian pharma exports to the US worth more than $2bn in 2024, it would hit producers Down Under hard. Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous products, such as bandages. 'We'll be putting (an) initially small tariff on pharmaceuticals,' Mr Trump told US business news channel CNBC. 'In one year, 1½ years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country.' He did not say what the initial rate would be, but earlier in the year he said duties on the sector would start from 25 per cent.
The Australian
2 days ago
- The Australian
Long Shortz with Airtasker: FY25 free cash flow and global growth surge
Tylah Tully chats with Airtasker (ASX:ART) CEO Tim Fung after the company reported a strong end to FY25, posting over $1 million in positive free cash flow and 29% growth in marketplace revenue. Growth was driven by re-acceleration in Australia and rapid international expansion, with the UK business growing over 100% year-on-year and the US soaring by 750%. Backed by strategic media partnerships and city expansions, Airtasker is scaling predictably, and plans to continue reinvesting into brand awareness and platform development across all key markets. Watch the video to learn more. This video was developed in collaboration with Airtasker, a Stockhead client at the time of publishing. The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Sponsored Nova Minerals has released a conceptual processing flowsheet for its 1.24Moz RPM deposit in Alaska. Sponsored Rhythm Biosciences has announced that its second-generation ColoSTAT blood test detects colorectal cancer consistently across all stages of the disease.
The Australian
3 days ago
- The Australian
Heathrow unveils £49 bn expansion plan for third runway
London's Heathrow Airport on Friday unveiled a £49-billion ($65 billion) expansion plan, including the costs of building a long-awaited third runway, approved by the UK government after years of legal wrangling. The runway would cost £21 billion, with flights expected to take off within a decade, while the rest of the privately-funded investment will go toward expanding and modernising the airport. Heathrow, Europe's busiest airport by passenger numbers, said the expansion would provide at least 30 new daily routes, more domestic connections and improved flight times. The increased capacity would almost double the number of annual passengers from 84 million currently to up to 150 million passengers annually. "It has never been more important or urgent to expand Heathrow," said chief executive Thomas Woldbye. "We are effectively operating at capacity to the detriment of trade and connectivity," he added. Despite fierce opposition from environmentalists and local residents, London mayor Sadiq Khan and some Labour MPs, the Labour government backed the new runway in January in a bid to boost UK economic growth. It would be a rare expansion in Europe, where countries are split between efforts to reduce greenhouse gas emissions and the needs of a strategic sector that has seen demand grow. Heathrow has submitted its proposal for the 3,500 metre runway to the UK government, which has also invited a rival proposal. - Green trade-offs - Heathrow's proposal includes £12 billion to fund a new terminal and £15 billion for modernisation. "A third runway and supporting infrastructure can be ready within a decade, and the full investment across all terminals would take place over the coming decades," Heathrow said in a statement. UK Prime Minister Keir Starmer is determined to deliver major infrastructure projects to revive the UK economy that has struggled to take off since the party came to power a year ago. The government is expected to also back expansion at Gatwick airport, south of the capital, in October -- having recently approved upgrades to London's Stansted, Luton and City airports. Britain's Supreme Court ruled at the end of 2020 that Heathrow could build the third runway, overturning a legal decision to block construction on environmental grounds. Local residents "will see their lives put on hold for a few more years while more money and time is wasted on a doomed scheme," said Douglas Parr, policy director for Greenpeace UK. He added the plans "export more tourism wealth out of the UK in the most polluting way possible." Arora Group, one of Heathrow's largest landowners, on Thursday said it will submit a rival bid to build a shorter third runway, promising lower costs and less disruption to local residents and the environment. "This is the first time the government has invited a competing proposal for Heathrow expansion," the UK-based property and hotel firm said in a statement. British Airways owner IAG's chief executive Luis Gallego said the rival bid was "credible" as the group announced its net profit jumped 44 percent to 1.3 billion euros ($1.5 billion) in the first six months of the year on "strong demand". "We always think that competition is good to improve things, and we have seen that in commercial aviation in the past," he added. Airport-owner Heathrow's latest investment proposal comes in addition to plans to invest £10 billion over the next five years in upgrades to boost passenger numbers, which would be largely funded by higher charges on airlines. ajb/jkb/rl
